Q2 FY27 — 4 Nov 2026
Lupin Limited Q2 FY27
Lupin delivered a steady Q2 FY27 with 11% YoY revenue growth to ₹7,827 crores, anchored by solid performance in India (+14.7% YoY) and Other Developed Markets (+46% YoY). However, profitability faced pressure as EBITDA margin dropped to 25.1% from 31.3% last year due to intensifying generic competition in Tolvaptan in the US and higher operating expenses. The company maintained its full-year FY27 guidance of USD 1.1-1.2 billion for US revenue and 24-25% EBITDA margin, supported by upcoming complex generics, 505(b)(2) launches like Apixaban, and biosimilars.
Read the full call






